Hemostemix $HEM has an agreement with Aspire Health Science.

Hemostemix (TSXV: HEM) primarily deals with developing and commercializing innovative blood-derived stem cell therapies. Is now entered into an agreement with Aspire and has agreed to settle the dispute of data stealth and intellectual property infringement regarding ACP-01.